Abstract
The antioxidant activity of reamberin was studied in children with epilepsy: 10 patients with epilepsy received intravenous reamberin (Research and Technological Pharmaceutical Firm POLYSAN, Saint Petersburg, Russia) 200 ml of 1,5 % infusion solution at a rate of 40-80 drops/min (2-4 ml/min) once daily for 5 days; 15 patients with epilepsy received only valporic acid (a control group). The efficacy of the medication was evaluated by the levels of lipid hydroperoxides, conjugated dienes, and malondialdehyde and by the activity of the main components of the antioxidant system (ceruloplasmin, vitamin E, catalase) in the blood of epileptic children. The administration of reamberin to patients with epilepsy significantly reduced the plasma levels of lipid hydroperoxides by 15 %, conjugated dienes by 15 %, and malondialdehyde by 24 % compared to the patients in the control group. An analysis of the effect of succinate-containing medications on the activity of the antioxidant system components revealed that the blood concentrations of ceruloplasmin and catalase were 37 % and 24 %, respectively, higher than those in the control group. Thus, the inclusion of reamberin into the treatment of children with epilepsy should be considered pathogenically justified, clinically reasonable, and promising.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
